NO951797L - Terapeutiske midler - Google Patents

Terapeutiske midler

Info

Publication number
NO951797L
NO951797L NO951797A NO951797A NO951797L NO 951797 L NO951797 L NO 951797L NO 951797 A NO951797 A NO 951797A NO 951797 A NO951797 A NO 951797A NO 951797 L NO951797 L NO 951797L
Authority
NO
Norway
Prior art keywords
alkyl
optionally substituted
halo
phenyl
alkoxy
Prior art date
Application number
NO951797A
Other languages
English (en)
Other versions
NO951797D0 (no
NO304467B1 (no
Inventor
John Rosindale Housley
James Edward Jeffery
Kenneth John Nichol
Bruce Jeremy Sargent
Original Assignee
Boots Co Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929223443A external-priority patent/GB9223443D0/en
Priority claimed from GB929223441A external-priority patent/GB9223441D0/en
Application filed by Boots Co Plc filed Critical Boots Co Plc
Publication of NO951797D0 publication Critical patent/NO951797D0/no
Publication of NO951797L publication Critical patent/NO951797L/no
Publication of NO304467B1 publication Critical patent/NO304467B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02—Seven-membered rings
    • C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D281/10—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO951797A 1992-11-09 1995-05-08 1,4-benzotiazepinforbindelser, anvendelse av dem og terapeutiske preparater inneholdende dem NO304467B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB929223443A GB9223443D0 (en) 1992-11-09 1992-11-09 Therapeutic agents
GB929223441A GB9223441D0 (en) 1992-11-09 1992-11-09 Therapeutic agents
PCT/EP1993/003123 WO1994011360A1 (en) 1992-11-09 1993-11-06 1,4-benzothiazepines useful as neurological agents

Publications (3)

Publication Number Publication Date
NO951797D0 NO951797D0 (no) 1995-05-08
NO951797L true NO951797L (no) 1995-05-24
NO304467B1 NO304467B1 (no) 1998-12-21

Family

ID=26301938

Family Applications (1)

Application Number Title Priority Date Filing Date
NO951797A NO304467B1 (no) 1992-11-09 1995-05-08 1,4-benzotiazepinforbindelser, anvendelse av dem og terapeutiske preparater inneholdende dem

Country Status (22)

Country Link
US (1) US5580866A (no)
EP (1) EP0667866B1 (no)
JP (1) JPH08503202A (no)
KR (1) KR100313649B1 (no)
AT (1) ATE163927T1 (no)
BG (1) BG62519B1 (no)
BR (1) BR9307387A (no)
CA (1) CA2148584A1 (no)
CZ (1) CZ288595B6 (no)
DE (1) DE69317436T2 (no)
DK (1) DK0667866T3 (no)
ES (1) ES2113081T3 (no)
FI (1) FI952204A0 (no)
GR (1) GR3026386T3 (no)
HU (1) HUT71819A (no)
NO (1) NO304467B1 (no)
NZ (1) NZ257843A (no)
PL (1) PL179401B1 (no)
RU (1) RU2115650C1 (no)
SK (1) SK280522B6 (no)
UA (1) UA41342C2 (no)
WO (1) WO1994011360A1 (no)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5939412A (en) * 1992-06-26 1999-08-17 Smithkline Beecham Corporation Bicyclic fibrinogen antagonists
ZA924760B (en) * 1991-06-28 1993-03-31 Smithkline Beecham Corp Bicyclic fibrinogen antagonists
MA23420A1 (fr) * 1994-01-07 1995-10-01 Smithkline Beecham Corp Antagonistes bicycliques de fibrinogene.
US6458784B1 (en) 1994-06-29 2002-10-01 Smithkline Beecham Corporation Vitronectin receptor antagonists
GB9506382D0 (en) * 1995-03-29 1995-05-17 Boots Co Plc Pharmaceutical compositions
US5977101A (en) * 1995-06-29 1999-11-02 Smithkline Beecham Corporation Benzimidazoles/Imidazoles Linked to a Fibrinogen Receptor Antagonist Template Having Vitronectin Receptor Antagonist Activity
ZA9610853B (en) 1995-12-29 1998-04-06 Smithkline Beecham Corp Processes and intermediates for preparing pharmaceuticals.
GB9616279D0 (en) * 1996-08-02 1996-09-11 Knoll Ag Chemical process
ES2198613T3 (es) * 1997-03-14 2004-02-01 Aventis Pharma Deutschland Gmbh 1,4-benzotiazepina-1,1-dioxidos hipolipidemicos.
GB9914745D0 (en) * 1999-06-24 1999-08-25 Knoll Ag Therapeutic agents
US7879840B2 (en) 2005-08-25 2011-02-01 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US7718644B2 (en) * 2004-01-22 2010-05-18 The Trustees Of Columbia University In The City Of New York Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
US7393652B2 (en) 2000-05-10 2008-07-01 The Trustees Of Columbia University In The City Of New York Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2)
US8022058B2 (en) 2000-05-10 2011-09-20 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US20040229781A1 (en) * 2000-05-10 2004-11-18 Marks Andrew Robert Compounds and methods for treating and preventing exercise-induced cardiac arrhythmias
US7544678B2 (en) 2002-11-05 2009-06-09 The Trustees Of Columbia University In The City Of New York Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2)
AU2004220548A1 (en) 2003-03-07 2004-09-23 The Trustees Of Columbia University, In The City Of New York Type 1 ryanodine receptor-based methods
US8710045B2 (en) 2004-01-22 2014-04-29 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the ryanodine receptors
US7704990B2 (en) * 2005-08-25 2010-04-27 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
WO2009111463A1 (en) * 2008-03-03 2009-09-11 Armgo Pharma, Inc. Process for preparing benzothiazepines from gamma-aminoalkylbenzenes
WO2013064231A1 (en) 2011-10-31 2013-05-10 Phenex Pharmaceuticals Ag SEVEN-MEMBERED SULFONAMIDES AS MODULATORS OF RAR-RELATED ORPHAN RECEPTOR-GAMMA (RORγ, NR1F3)
EP2708535A1 (en) 2012-05-11 2014-03-19 Les Laboratoires Servier Agents for treating disorders involving modulation of ryanodine receptors
KR102157141B1 (ko) 2018-11-27 2020-09-17 주식회사 파미니티 으아리 추출물을 유효 성분으로 포함하는 인지 기능 개선용 조성물
KR102172916B1 (ko) 2018-12-07 2020-11-02 주식회사 파미니티 실크 펩타이드 및 천연 추출물을 포함하는 인지 기능 개선용 조성물
AU2021381942A1 (en) * 2020-11-17 2023-06-29 Armgo Pharma, Inc. Agents for treating disorders involving ryanodine receptors
CN116887839A (zh) 2021-01-08 2023-10-13 阿姆果制药有限公司 兰诺定受体调节剂的结晶形式及其用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3362962A (en) * 1964-01-24 1968-01-09 Hoffmann La Roche Certain benzothiazepine derivatives
US3682962A (en) * 1970-03-17 1972-08-08 Sterling Drug Inc 1-substituted-1,2,3,5-tetrahydro-4,1-benzothiozepines
EP0368063B1 (de) * 1988-11-05 1992-06-10 Bayer Ag Verfahren zur Kernchlorierung von aromatischen Kohlenwasserstoffen
JP2703408B2 (ja) * 1990-12-28 1998-01-26 麒麟麦酒株式会社 １，４‐ベンゾチアゼピン誘導体
GB9111376D0 (en) * 1991-05-25 1991-07-17 Boots Co Plc Therapeutic agents
GB9203347D0 (en) * 1992-02-17 1992-04-01 Wellcome Found Hypolipidaemic compounds

Also Published As

Publication number Publication date
FI952204A (fi) 1995-05-08
PL179401B1 (pl) 2000-08-31
KR100313649B1 (ko) 2002-02-28
BG62519B1 (bg) 2000-01-31
CZ288595B6 (cs) 2001-07-11
RU95112484A (ru) 1997-04-20
NO951797D0 (no) 1995-05-08
HUT71819A (en) 1996-02-28
DK0667866T3 (da) 1998-05-25
SK58895A3 (en) 1995-09-13
CA2148584A1 (en) 1994-05-26
ES2113081T3 (es) 1998-04-16
EP0667866A1 (en) 1995-08-23
EP0667866B1 (en) 1998-03-11
US5580866A (en) 1996-12-03
BG99679A (bg) 1996-04-30
JPH08503202A (ja) 1996-04-09
SK280522B6 (sk) 2000-03-13
DE69317436D1 (de) 1998-04-16
NZ257843A (en) 1996-10-28
NO304467B1 (no) 1998-12-21
AU680639B2 (en) 1997-08-07
ATE163927T1 (de) 1998-03-15
UA41342C2 (uk) 2001-09-17
GR3026386T3 (en) 1998-06-30
FI952204A0 (fi) 1995-05-08
WO1994011360A1 (en) 1994-05-26
AU5464494A (en) 1994-06-08
DE69317436T2 (de) 1998-07-02
KR950704283A (ko) 1995-11-17
CZ117695A3 (en) 1996-06-12
HU9501352D0 (en) 1995-06-28
RU2115650C1 (ru) 1998-07-20
PL308757A1 (en) 1995-08-21
BR9307387A (pt) 1999-08-31

Similar Documents

Publication Publication Date Title
BR9307387A (pt) Agentes terapêuticos
NO961435L (no) Terapeutiske midler
GB9309749D0 (en) Therapeutic agents
AU7185194A (en) Isoquinoline derivatives as therapeutic agents
ZA938302B (en) Therapeutic agents
JO1728B1 (en) Therapeutic agents
JO1785B1 (en) Therapeutic agents
JO1809B1 (en) Therapeutic agents

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees

Free format text: LAPSED IN MAY 2003